Glaukos Corporation

NYSE:GKOS

Medical - Devices

Healthcare
$233.08 -0.14%

-$0.18 today

Market cap
$13.80B
Beta
0.81
P/E (TTM)
-39.0
EPS (TTM)
-$3.26
52W Low $73.16High $148.11

Volume 1.12M

Average 0.94M

GKOS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Glaukos CorporationNYSE: GKOS

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue grows in line with its trailing trend

Q2 FY2026 cost of revenue of $34.02M rose 26.5% year over year, ahead of the +24.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +18.3% a year.

Context

  • Cost of revenue amounted to 22.5% of revenue in FY2025, down 2.0 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +26.5% holds above the trailing-twelve-month pace of +24.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$34.02M+2.0% QoQ
Last fiscal yearDec 2025
$114.23M+21.5% YoY
LTMJun 2026
$127.96M+24.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.5%——
1 year+21.5%——
3-year CAGR+18.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
114.23M USD
Year-over-year change
+21.5%
4-year CAGR
+14.4%

Cost of Revenue vs competitors

How GKOS compares with its peers on the latest reported figures

  • GKOS's LTM Jun 2026 cost of revenue of $127.96M is the 3rd highest of the 9 companies compared; the peer median is $20.15M.
  • Its year-over-year change of +24.9% is the highest of 8, against a peer median of -1.8%.
  • Cost of revenue amounts to 20.9% of revenue for GKOS, versus a peer median of 23.5%.
GKOS Competitors Peer median
Cost of Revenue for GKOS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALCAlcon Inc.LTM Sep 2026$4.67B +2.1%+5.5%42.7%
BLCOBausch + Lomb CorporationLTM Jun 2026$2.28B +8.0%+15.0%42.8%
GKOSGlaukos CorporationLTM Jun 2026$127.96M +24.9%+18.3%20.9%
STAASTAAR Surgical CompanyLTM Apr 2026$68.44M -5.7%-2.2%23.6%
RXSTRxSight, Inc.LTM Mar 2026$29.3M -43.5%+4.4%23.0%
SGHTSight Sciences, Inc.LTM Mar 2026$11M -1.8%-4.7%13.8%
OCULOcular Therapeutix, Inc.LTM Mar 2026$6.64M +19.4%+13.1%12.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$1.79M -52.4%-37.2%23.5%
SGPSpyGlass Pharma, Inc. Common StockFY2025$612K ———
Peer median (excluding GKOS) $20.15M-1.8%+4.4%23.5%

Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue294.01M282.86M314.71M383.48M507.44M
Cost of Revenue66.63M68.98M75.58M94.03M114.23M
Gross Profit227.38M213.88M239.14M289.45M393.22M
Gross Margin77.3%75.6%76.0%75.5%77.5%
Research & Development101M123.27M138.77M136.43M150.61M
Selling, General & Admin179.26M192.93M224.07M262.85M329.34M
Operating Expenses260.26M296.2M367.84M411.82M479.95M
Depreciation & Amortization34.42M35.95M37.98M39.92M42.35M
EBITDA(1.47M)(48.76M)(82.12M)(95.64M)(146.06M)
EBITDA Margin-0.5%-17.2%-26.1%-24.9%-28.8%
Operating Income(32.87M)(82.31M)(128.7M)(122.37M)(86.73M)
Operating Margin-11.2%-29.1%-40.9%-31.9%-17.1%
Interest Income1.29M2.38M9.16M11.11M10.71M
Interest Expense13.37M13.72M13.63M10.04M4.64M
Other Income / Expenses(16.4M)(16.12M)(5.03M)(23.24M)(106.31M)
Income Before Tax(49.27M)(98.43M)(133.73M)(145.6M)(193.04M)
Pre-Tax Margin-16.8%-34.8%-42.5%-38.0%-38.0%
Income Tax Expense326K766K934K771K(5.35M)
Net Income(49.59M)(99.2M)(134.66M)(146.37M)(187.69M)
Net Margin-16.9%-35.1%-42.8%-38.2%-37.0%
EPS (Basic)(1.07)(2.09)(2.78)(2.77)(3.28)
EPS (Diluted)(1.07)(2.09)(2.78)(2.77)(3.28)
Weighted Avg Shares46.42M47.44M48.43M52.76M57.19M
Weighted Avg Shares (Diluted)46.42M47.44M48.43M52.76M57.19M

Glaukos Corporation

NYSE:GKOS

Intrinsic Alpha fair value

Locked

Current Price

$233.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.